Stock-Based Compensation - Stock Options Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares
Number of Shares
Outstanding at the beginning	1,501,193
Granted	1,790,654
Exercised	(1,960)
Forfeited	(59,433)
Outstanding at the end	3,230,454	1,501,193
Vested and exercisable at the end	1,644,088
Weighted- Average Exercise Price
Outstanding at the beginning (in dollars per share) | $ / shares	$ 8.37
Granted (in dollars per share) | $ / shares	3.59
Exercised (in dollars per share) | $ / shares	3.61
Forfeited (in dollars per share) | $ / shares	10.21
Outstanding at the end (in dollars per share) | $ / shares	5.23	$ 8.37
Vested and exercisable at the end (in dollars per share) | $ / shares	$ 5.87
Weighted-Average Remaining Contractual Term (years)
Outstanding (in years)	7 years 6 months	7 years 9 months 18 days
Vested and exercisable (in years)	6 years 1 month 6 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value (in dollars) | $	$ 621
Vested and exercisable at the end (in dollars) | $	$ 353
Other Disclosures
Weighted average grant date fair value of options granted | $ / shares	$ 2.38
Employee Stock Option
Stock-Based Compensation
Exercise price as a percentage of market value of share of common stock at closing on the date of the grant	100.00%
Contractual term	10 years
Other Disclosures
Total unrecognized compensation expense | $	$ 3,800
Weighted-average recognition period	2 years
Employee Stock Option | Minimum
Stock-Based Compensation
Vesting period	3 years
Employee Stock Option | Maximum
Stock-Based Compensation
Vesting period	4 years
Options that vest 10th day after FDA's approval of CanGarooRM product
Number of Shares
Granted	397,640
Options that vest on achievements of price thresholds
Number of Shares
Granted	162,500
Outstanding at the end	345,011
Other Disclosures
Share price threshold period	20 days
Period to recognize costs	3 years